MedKoo Cat#: 471039 | Name: 8-M-PDOT
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

8-M-PDOT is a selective melatonin receptor agonist

Chemical Structure

8-M-PDOT
8-M-PDOT
CAS#134865-70-6

Theoretical Analysis

MedKoo Cat#: 471039

Name: 8-M-PDOT

CAS#: 134865-70-6

Chemical Formula: C14H19NO2

Exact Mass: 233.1416

Molecular Weight: 233.31

Elemental Analysis: C, 72.07; H, 8.21; N, 6.00; O, 13.71

Price and Availability

Size Price Availability Quantity
10mg USD 350.00 2 weeks
50mg USD 850.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
AH 002, AH002, AH-002, 8-M-PDOT
IUPAC/Chemical Name
N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide
InChi Key
RVIGBTUDFAGRTQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H19NO2/c1-3-14(16)15-11-8-7-10-5-4-6-13(17-2)12(10)9-11/h4-6,11H,3,7-9H2,1-2H3,(H,15,16)
SMILES Code
CCC(NC1CC2=C(C=CC=C2OC)CC1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 233.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Noseda, A.C., Targa, A.D., Rodrigues, L.S., et al. REM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effects. Sleep Sci. 9(1), 47-54 (2016). 2. Browning, C., Beresford, I., Fraser, N., et al. Pharmacological characterization of human recombinant melatonin mt1 and MT2 receptors. Br. J. Pharmacol. 129(5), 877-886 (2000). 3. Dubocovich ML, Masana MI, Iacob S, Sauri DM., Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor., Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75. 4. Dubocovich ML, Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995 Feb;16(2):50-6.